Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company ...( Conference Call To Be Held Tuesday ...)

Conference Call To Be Held Tuesday, April 1, 2008 At 10:00 a.m. Eastern

Daylight Time

HOPKINTON, Mass., March 31 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today reported consolidated financial results for the year ended December 31, 2007 and company highlights.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

"2007 was a year of significant clinical, regulatory, pipeline and business accomplishments that helped advance our mission of building a leading biopharmaceutical company focused on disorders of the central nervous system," commented Peter G. Savas, Chairman and Chief Executive Officer of Alseres. "Our progress reinforces our confidence in the broad potential of our pipeline and in our leadership in nerve repair and regenerative therapeutics. Our focus in 2008 will be on commencing the Phase IIb trial of CETHRIN, partnering our molecular imaging assets and closing collaborations for our regenerative therapeutics."

2007 and Recent Corporate Highlights

Product Pipeline and Scientific Highlights

Advanced the Regenerative Therapeutics pipeline.

-- In April 2007, the Company reported 6-month interim data from its Phase

I/IIa Clinical Trial in Acute Spinal Cord Injury on the first 37

subjects treated with CETHRIN at doses up to 6 mg. The data indicated

that CETHRIN was safe and well tolerated. The overall population of

patients treated with CETHRIN demonstrated an improvement in their

impairment level on the American Spinal Injury Association scale that

was approximatel
'/>"/>